Cargando…
First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
BACKGROUND: Treatment of frail patients with advanced colorectal cancer (CRC) is controversial. This pilot phase II trial aimed to assess the efficacy and safety of regorafenib when administered in first-line to frail patients with advanced CRC. METHODS: Frail patients without prior advanced colorec...
Autores principales: | Carrato, A., Benavides, M., Massutí, B., Ferreiro-Monteagudo, R., García Alfonso, P., Falcó, E., Reboredo, M., Cano, T., Gallego, J., Viéitez, J. M., Layos, L., Salud, A., Polo, E., Dotor, E., Durán-Ogalla, G., Rodriguez-Garrote, M., Calvo, A., Grande, E., Aranda, E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547483/ https://www.ncbi.nlm.nih.gov/pubmed/31159765 http://dx.doi.org/10.1186/s12885-019-5753-7 |
Ejemplares similares
-
Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study
por: Conde, Elisa, et al.
Publicado: (2021) -
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy
por: Martinez-Balibrea, E, et al.
Publicado: (2010) -
Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study
por: Díaz-Rubio, Eduardo, et al.
Publicado: (2012) -
Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials
por: Benavides, Manuel, et al.
Publicado: (2019) -
Update of TTD: Therapeutic Target Database
por: Zhu, Feng, et al.
Publicado: (2010)